Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence Friedlander

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
JCO Precision Oncology|July 12, 2021
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion SequencingEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Scientific Reports|March 4, 2021
Cell-free DNA concentration and fragment size as a biomarker for prostate cancerEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Cancer Medicine|October 12, 2021
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancerStacey A Kenfield, Erin L Van Blarigan, Neil Panchal, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
JCO Precision Oncology|July 12, 2021
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion SequencingEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Scientific Reports|March 4, 2021
Cell-free DNA concentration and fragment size as a biomarker for prostate cancerEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Cancer Medicine|October 12, 2021
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancerStacey A Kenfield, Erin L Van Blarigan, Neil Panchal, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Pageof 4